$ACUT News
Last published 10mo ago
- 10mo agoACUTAccuStem Sciences Announces StemPrintER Pilot Study with National Surgical Adjuvant Breast and Bowel Project (NSABP)GlobeNewswirePHOENIX, Jan. 08, 2026 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB:ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with or at risk of cancer, today announced the
- 1y agoACUTDRMAHMTXFINM+4Life Sciences Virtual Investor Forum: Presentations Now Available for Online ViewingGlobeNewswireNEW YORK, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the Life Sciences Virtual Investor Forum, held
- 1y agoACUTAccuStem Sciences and EmeritusDX Expand Blood-Based Testing Capabilities to Advance Cancer Diagnostics and Treatment PlanningGlobeNewswirePHOENIX, Ariz. and LONDON, Sept. 17, 2025 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB:ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with or at risk of cancer, today
- 1y agoACUTAccuStem Sciences to Present at the Life Sciences Virtual Investor Forum September 18thGlobeNewswirePHOENIX and LONDON, Sept. 16, 2025 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB:ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with or at risk of cancer, today
- 1y agoACUTAccuStem Sciences, Inc. Announces Chairman Purchase of SharesGlobeNewswireLONDON, June 13, 2025 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB:ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with cancer, announced that its Chairman of the Board,
- 1y agoACUTAccuStem Sciences, Inc. and EmeritusDX Announce Partnership to Commercialize MSC Test for Lung Cancer ScreeningGlobeNewswireLONDON and PHOENIX, Ariz., April 28, 2025 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB:ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with or at risk of cancer, and
- 1y agoACUTAccuStem Sciences, Inc. Announces Chairman Purchase of SharesGlobeNewswireLONDON and PHOENIX, Ariz., April 21, 2025 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB:ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with cancer, announced that its
- 1y agoACUTAccuStem Sciences, Inc. Signs Agreement to Access Blood Samples from Lung Cancer Screening Trial to Expedite MSC Commercialization PlanGlobeNewswireLONDON and PHOENIX, April 16, 2025 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB:ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with or at risk of cancer, today announced
- 1y agoACUTAccuStem Sciences, Inc. Announces Chairman Purchase of SharesGlobeNewswireLONDON and PHOENIX, April 08, 2025 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB:ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with cancer, announced that its Chairman of
- 1y agoACUTAccuStem Sciences to Offer its MSC Blood Test to Lung Cancer Screening Programs in the United StatesGlobeNewswireLONDON and PHOENIX, April 04, 2025 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB:ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with or at risk of cancer, announces plans
- 1y agoACUTAccuStem Sciences, Inc. Announces Acquisition of Proprietary MSC Lung Cancer Screening TestGlobeNewswireAccuStem pursuing strategic commercialization plan intending to launch the MSC test in the US in 2026 LONDON and PHOENIX, Ariz., March 18, 2025 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB:ACUT), a clinical
- 1y agoACUTAccuStem Sciences, Inc. Announces Chairman Purchase of SharesGlobeNewswireLONDON and PHOENIX, Jan. 03, 2025 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB:ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with cancer, announced that its Chairman of
- 3y agoACUTEXASAccuStem Sciences, Inc. and EmeritusDX Announce Joint Product Development Agreement and Strategic PartnershipGlobeNewswireLONDON and PHOENIX, July 17, 2023 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB:ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with cancer, and EmeritusDX, a rapidly
- 3y agoACUTAccuStem Sciences, Inc. Extends and Broadens Partnership with Instituto Europeo di Oncologia (IEO) Enabling its Strategic Approach to Address Unanswered Clinical Questions in Early Stage Breast CancerGlobeNewswireStemPrintER outperformed the current market leader, OncotypeDX test, in stratifying patients according to their risk of breast cancer recurrence LONDON and PHOENIX, July 11, 2023 (GLOBE NEWSWIRE) -- AccuStem
- 3y agoACUTAccuStem Sciences, Inc. Announces Collaboration Agreement with University HospitalsGlobeNewswireLONDON and PHOENIX, Ariz., June 06, 2023 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB:ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with cancer, today announced the
- 3y agoACUTAccuStem Announce Strategic Clinical and Operational PartnershipGlobeNewswireLONDON and PHOENIX, May 31, 2023 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB:ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with cancer, today announced a strategic plan
- 3y agoACUTAccuStem Sciences Announces Extension of its US Patent Application for SPARE Test for Patients with Breast CancerGlobeNewswireLONDON and PHOENIX, May 02, 2023 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB:ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with cancer, announced today that it is
- 3y agoACUTAccuStem Sciences, Inc. Announces Chairman Purchase of SharesGlobeNewswireLONDON and PHOENIX, Dec. 06, 2022 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB:ACUT), a life sciences company dedicated to improving outcomes for patients with cancer, announced that its Chairman of the Board,
- 3y agoACUTAccuStem Sciences, Inc. Announces Chairman Purchase of SharesGlobeNewswireLONDON and PHOENIX, Nov. 22, 2022 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB:ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with cancer, announced that its Chairman of
- 3y agoACUTAccuStem Sciences Announces Appointment of Sean McDonald to Board of DirectorsGlobeNewswireLONDON and PHOENIX, Nov. 16, 2022 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB:ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with cancer, announced today the appointment
- 4y agoACUTAccuStem Announces Adjournment of Annual Meeting of StockholdersGlobeNewswireLONDON and PHOENIX, Oct. 10, 2022 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB:ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with cancer, announced today that its 2022
- 4y agoACUTAccuStem Sciences Announces Issuance of US Patent for StemPrintER Test for Patients with Breast CancerGlobeNewswireLONDON and PHOENIX, Ariz., Sept. 13, 2022 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB:ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with cancer, announced today that the US Patent and Trademark Office h
- 4y agoACUTAccuStem Sciences, Inc. Announces Chairman Purchase of SharesGlobeNewswireLONDON and PHOENIX, Ariz., June 09, 2022 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB:ACUT), a life sciences company dedicated to improving outcomes for patients with cancer, announced that its Chairman of the Board, Mr. Gabriele Cerrone, has not
- 4y agoACUTAccuStem Sciences, Inc. Announces Chairman Purchase of SharesGlobeNewswireLONDON and PHOENIX, April 28, 2022 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB:ACUT), a life sciences company dedicated to improving outcomes for patients with cancer, announced that its Chairman of the Board, Mr. Gabriele Cerrone, has notified
- 4y agoACUTAccuStem Sciences, Inc. Announces DTC EligibilityGlobeNewswireLONDON and PHOENIX, April 14, 2022 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB:ACUT), a life sciences company dedicated to improving outcomes for patients with cancer, is pleased to announce its uplisting from the OTC Pink Sheets to the OTCQB®�